Adenovirus vectored vaccines are a highly eective strategy to induce cellular immune\nresponses which are particularly eective against intracellular pathogens. Recombinant simian\nadenovirus vectors were developed to circumvent the limitations imposed by the use of human\nadenoviruses due to widespread seroprevalence of neutralising antibodies. We have constructed\na replication deficient simian adenovirus-vectored vaccine (ChAdOx2) expressing 4 genes from\nthe Mycobacterium avium subspecies paratuberculosis (AhpC, Gsd, p12 and mpa). Safety and T-cell\nimmunogenicity results of the first clinical use of the ChAdOx2 vector are presented here. The trial\nwas conducted using a â??three-plus-threeâ?? dose escalation study design. We demonstrate the vaccine is\nsafe, well tolerated and immunogenic.
Loading....